Lv1
50 积分 2022-10-11 加入
Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents
3个月前
已关闭
Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
4个月前
已完结
Acquisition of Lymphokine-Producing Phenotype by CD4+ T Cells
4个月前
已完结
CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual targeting antibody overcome antigen heterogeneity in AML
5个月前
已完结
Regulatory T cells converted from Th1 cells in tumors suppress cancer immunity via CD39
5个月前
已完结
T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct
5个月前
已完结
ATOR-4066, a bispecific antibody targeting CD40 and CEACAM5, induces strong myeloid and T cell–dependent tumor immunity and synergizes with PD-1 blockade
5个月前
已完结
Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies
5个月前
已完结
T cell-engaging therapies — BiTEs and beyond
5个月前
已完结
Bispecific T cell engager therapy for refractory rheumatoid arthritis
5个月前
已完结
皖公网安备34019202002308
